Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.

Chukwueke UN, Wen PY.

CNS Oncol. 2019 Mar 1;8(1):CNS28. doi: 10.2217/cns-2018-0007. Epub 2019 Feb 26. No abstract available.

2.

Response Assessment in Neuro-Oncology Clinical Trials.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ.

J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. Review.

3.

Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.

Huang RY, Wen PY.

Magn Reson Imaging Clin N Am. 2016 Nov;24(4):705-718. doi: 10.1016/j.mric.2016.06.003. Epub 2016 Sep 14. Review.

PMID:
27742111
4.

Imaging Criteria in Neuro-oncology.

Nowosielski M, Wen PY.

Semin Neurol. 2018 Feb;38(1):24-31. doi: 10.1055/s-0038-1627468. Epub 2018 Mar 16. Review.

PMID:
29548049
5.

Assessment of Brain Tumor Response: RANO and Its Offspring.

Eisele SC, Wen PY, Lee EQ.

Curr Treat Options Oncol. 2016 Jul;17(7):35. doi: 10.1007/s11864-016-0413-5. Review.

PMID:
27262709
6.

Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.

Jaspan T, Morgan PS, Warmuth-Metz M, Sanchez Aliaga E, Warren D, Calmon R, Grill J, Hargrave D, Garcia J, Zahlmann G.

AJNR Am J Neuroradiol. 2016 Sep;37(9):1581-7. doi: 10.3174/ajnr.A4782. Epub 2016 Apr 28.

7.

Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.

Sharma M, Juthani RG, Vogelbaum MA.

Chin Clin Oncol. 2017 Aug;6(4):37. doi: 10.21037/cco.2017.06.26. Review.

8.

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group.

Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW.

Pediatr Blood Cancer. 2013 Sep;60(9):1397-401. doi: 10.1002/pbc.24562. Epub 2013 Apr 26.

9.

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.

Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM.

Neurosurgery. 2012 Jan;70(1):234-43; discussion 243-4. doi: 10.1227/NEU.0b013e318223f5a7. Review.

PMID:
21593697
10.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.

PMID:
28646771
11.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

12.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

13.

Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.

Auer TA, Breit HC, Marini F, Renovanz M, Ringel F, Sommer CJ, Brockmann MA, Tanyildizi Y.

J Neuroradiol. 2019 Feb;46(1):36-43. doi: 10.1016/j.neurad.2018.04.002. Epub 2018 May 4.

PMID:
29733920
14.

Neuroradiological response criteria for high-grade gliomas.

Lutz K, Radbruch A, Wiestler B, Bäumer P, Wick W, Bendszus M.

Clin Neuroradiol. 2011 Nov;21(4):199-205. doi: 10.1007/s00062-011-0080-7. Epub 2011 Jun 17. Review.

PMID:
21681688
15.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA.

Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1. Review.

16.

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY.

Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21.

17.

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2012 May;14(5):667-73. doi: 10.1093/neuonc/nos070. Epub 2012 Apr 4.

18.

Pros and cons of current brain tumor imaging.

Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii2-11. doi: 10.1093/neuonc/nou224. Review.

19.

Comparing available criteria for measuring brain metastasis response to immunotherapy.

Qian JM, Mahajan A, Yu JB, Tsiouris AJ, Goldberg SB, Kluger HM, Chiang VLS.

J Neurooncol. 2017 May;132(3):479-485. doi: 10.1007/s11060-017-2398-8. Epub 2017 Mar 8.

PMID:
28275886
20.

Response assessment criteria for brain metastases: proposal from the RANO group.

Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. Review.

PMID:
26065612

Supplemental Content

Support Center